Results 11 to 20 of about 1,594,004 (375)

Effectiveness of Acceptance and Commitment Therapy in Reducing High-risk and Harmful Behaviors in Students [PDF]

open access: yesمجله علوم پزشکی صدرا, 2023
Introduction: The prevalence of high-risk behaviors in young people is one of the concerns of societies. This study aimed to evaluate the effectiveness of Acceptance and Commitment therapy in reducing high-risk and harmful behaviors among high school ...
Zahra Alizadeh, Abbas Rohani
doaj   +1 more source

Noncoding RNA therapeutics — challenges and potential solutions

open access: yesNature reviews. Drug discovery, 2021
Therapeutic targeting of noncoding RNAs (ncRNAs), such as microRNAs (miRNAs) and long noncoding RNAs (lncRNAs), represents an attractive approach for the treatment of cancers, as well as many other diseases.
Melanie Winkle   +3 more
semanticscholar   +1 more source

Therapeutic effects of diosgenin on alveolar bone loss and apoptosis in diabetic rats with experimental periodontitis [PDF]

open access: yesIranian Journal of Basic Medical Sciences, 2023
Objective(s): The present study aims to evaluate the efficacy of administered diosgenin (DG) which has anti-oxidant and anti-inflammatory effects, on alveolar bone loss (ABL) and apoptosis in diabetic rats with periodontitis. Materials and Methods: Forty
Alper Kızıldağ   +4 more
doaj   +1 more source

Engineering cytokine therapeutics

open access: yesNature Reviews Bioengineering, 2023
Cytokines have pivotal roles in immunity, making them attractive as therapeutics for a variety of immune-related disorders. However, the widespread clinical use of cytokines has been limited by their short blood half-lives and severe side effects caused ...
Jeroen Deckers   +15 more
semanticscholar   +1 more source

Engineering siRNA therapeutics: challenges and strategies

open access: yesJournal of Nanobiotechnology, 2023
Small interfering RNA (siRNA) is a potential method of gene silencing to target specific genes. Although the U.S. Food and Drug Administration (FDA) has approved multiple siRNA-based therapeutics, many biological barriers limit their use for treating ...
Syed Saqib Ali Zaidi   +5 more
semanticscholar   +1 more source

Antibody-based binding domain fused to TCRγ chain facilitates T cell cytotoxicity for potent anti-tumor response

open access: yesOncogenesis, 2023
Chimeric antigen receptor T-cell (CAR-T) therapy has demonstrated potent clinical efficacy in the treatment of hematopoietic malignancies. However, the application of CAR-T in solid tumors has been limited due in part to the expression of inhibitory ...
Zhao Chen   +25 more
doaj   +1 more source

A spoonful of sugar: the application of glycopolymers in therapeutics [PDF]

open access: yes, 2011
Glycopolymers, synthetic polymers displaying carbohydrate moieties, have been linked to many potential applications at the biology–chemistry interface. One area that holds particular promise is the employment of glycopolymers as vehicles for therapeutics
Cameron, Neil R., Spain, Sebastian G.
core   +2 more sources

PEGylated therapeutics in the clinic

open access: yesBioengineering & Translational Medicine, 2023
The covalent attachment of polyethylene glycol (PEG) to therapeutic agents, termed PEGylation, is a well‐established and clinically proven drug delivery approach to improve the pharmacokinetics and pharmacodynamics of drugs.
Yongsheng Gao   +3 more
semanticscholar   +1 more source

The CNS-penetrant soluble guanylate cyclase stimulator CYR119 attenuates markers of inflammation in the central nervous system

open access: yesJournal of Neuroinflammation, 2021
Background Inflammation in the central nervous system (CNS) is observed in many neurological disorders. Nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate (NO–sGC–cGMP) signaling plays an essential role in modulating neuroinflammation.
Susana S. Correia   +16 more
doaj   +1 more source

Pregabalin: a range of misuse-related unanswered questions [PDF]

open access: yes, 2019
© 2019 The Authors.
Chiappini, Stephania, Schifano, Fabrizio
core   +2 more sources

Home - About - Disclaimer - Privacy